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6MWT

:   6‐Minute Walk Test

BMD

:   Becker muscular dystrophy

DMD

:   Duchenne muscular dystrophy

MBF

:   maximum bite force

N

:   Newton

QMUS

:   quantitative muscle ultrasound

SLT

:   speech language therapist

1. INTRODUCTION {#mus26771-sec-0005}
===============

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are neuromuscular disorders caused by an X‐linked mutation in the dystrophin gene. This mutation results in a decreased level (BMD) or absence (DMD) of functional dystrophin.[1](#mus26771-bib-0001){ref-type="ref"} Mastication (ie, chewing) and swallowing problems due to weakness of orofacial muscles are observed in patients with either DMD or BMD. In a previous study of DMD patients in the early and late ambulatory stages, 60% had mastication difficulties.[2](#mus26771-bib-0002){ref-type="ref"} In another study of DMD patients (9--26 years old), 90% had swallowing problems when assessed with videofluoroscopy.[3](#mus26771-bib-0003){ref-type="ref"} There is more literature on DMD than on BMD in this respect, but in both populations orofacial muscle weakness may lead to mastication and swallowing difficulties.[2](#mus26771-bib-0002){ref-type="ref"}, [3](#mus26771-bib-0003){ref-type="ref"}, [4](#mus26771-bib-0004){ref-type="ref"}, [5](#mus26771-bib-0005){ref-type="ref"}, [6](#mus26771-bib-0006){ref-type="ref"}, [7](#mus26771-bib-0007){ref-type="ref"} Using quantitative muscle ultrasound (QMUS) in patients with DMD, hypertrophy and pseudohypertrophy of the orofacial muscles (temporalis muscle and tongue) have been reported.[2](#mus26771-bib-0002){ref-type="ref"} In addition, previous research has shown a significantly reduced maximum bite force (MBF) in all ambulatory stages of DMD, leading to mastication difficulties.[2](#mus26771-bib-0002){ref-type="ref"}, [8](#mus26771-bib-0008){ref-type="ref"} Of interest, in BMD patients, a similar level of swallowing problems has been found as in patients with DMD when groups were matched according to their functional capacities.[5](#mus26771-bib-0005){ref-type="ref"}

QMUS of the orofacial muscles is useful to explain underlying mechanisms of mastication and swallowing problems.[9](#mus26771-bib-0009){ref-type="ref"}, [10](#mus26771-bib-0010){ref-type="ref"}, [11](#mus26771-bib-0011){ref-type="ref"} QMUS has previously been used in patients with DMD to assess the muscle abnormality underlying dysphagia,[2](#mus26771-bib-0002){ref-type="ref"}, [6](#mus26771-bib-0006){ref-type="ref"} but no data on thickness or echogenicity of orofacial muscles are available for patients with BMD.

Although BMD patients have a milder disease progression in terms of ambulatory capacity than those with DMD, our clinical experience suggests that impaired mastication and swallowing occur early in BMD relative to their limb muscle involvement. This notion has led to the hypothesis that the orofacial muscles of BMD patients may show severe dystrophic changes compared with DMD patients, relative to ambulatory capacity. Confirmation of this hypothesis is important to gain insight into the clinical course of BMD and to evaluate whether early assessment of mastication and swallowing difficulties in BMD is warranted. Hence, the aim of this study was to assess differences in dystrophic changes of orofacial muscles and mastication and swallowing difficulties between DMD and BMD patients in relation to their ambulatory capacity.

2. METHODS {#mus26771-sec-0006}
==========

2.1. Participants {#mus26771-sec-0007}
-----------------

The charts of patients with a genetically confirmed diagnosis of DMD or BMD (in‐frame vs out‐of‐frame exon deletions) who visited the interdisciplinary outpatient clinic of the pediatric and adult center for neuromuscular disorders of the Radboud University Medical Center between December 2015 and December 2016 were reviewed. All patients who were still in the early ambulatory stage were included for analysis.[12](#mus26771-bib-0012){ref-type="ref"} Data had been collected during the annual visits as part of their regular care. The research was conducted in accordance with national and international ethics standards. The study was approved by the regional medical‐ethical committee, and informed consent was waived because of the retrospective nature of the study.

2.2. Assessment {#mus26771-sec-0008}
---------------

At each visit, all patients were seen by a speech language therapist (SLT) and a physiotherapist. Only data from standardized parts of the SLT assessment (questionnaire, MBF measurements, and QMUS) were included for analysis. Age, height, weight, and corticosteroid treatment of the patients were noted. The 6‐Minute Walk Test (6MWT) was performed by the physiotherapist. The number of meters walked was used to assess patients' walking capacity. This number was corrected for age and described as a z‐score.[13](#mus26771-bib-0013){ref-type="ref"}

### 2.2.1. Questionnaire {#mus26771-sec-0009}

Mastication and swallowing symptoms were determined using a semi‐structured questionnaire about feeding difficulties.[6](#mus26771-bib-0006){ref-type="ref"} Items pertaining to mastication difficulties, symptoms of choking (thin liquid and solid food), and food sticking in the throat were scored on a 4‐point scale (1, no problems; 2, once a week; 3, once a day; 4, several times a day). These scores were used to determine whether patients had mastication and/or swallowing difficulties. The scores on the questionnaire were dichotomized (1 indicating no difficulties and 2--4 indicating incremental difficulties).

### 2.2.2. MBF {#mus26771-sec-0010}

The MBF was measured using the Bite Force Gauge of the VU university (VU‐BFG, Amsterdam, the Netherlands), a device to measure maximum voluntary bite force in kilograms.[14](#mus26771-bib-0014){ref-type="ref"} The VU‐BFG was placed between the incisors of the patients. The patients were asked to bite three times as firmly as possible. The maximum value in kilograms was converted to Newtons to make it comparable to the literature.[2](#mus26771-bib-0002){ref-type="ref"} The MBF was corrected for height and converted to a z‐score (based on our own laboratory values and regression analysis of 68 healthy participants).[2](#mus26771-bib-0002){ref-type="ref"} z‐Scores were calculated using the following equation:$$z = \frac{\frac{\mathit{MBF}\ \textit{in}\ N}{9.807} - \left( {- 21.5 + \left( {0.266*\textit{height}} \right)} \right)}{7.2}$$

### 2.2.3. QMUS {#mus26771-sec-0011}

For all examinations the z.one ultra Convertible Ultrasound system (Zonare medical systems, Mountain View, CA) was used. QMUS was performed to determine muscle thickness and echogenicity of the masticatory muscles (masseter muscle and temporalis muscle), submental muscles (digastric muscles and geniohyoid muscles), and the muscles of the tongue (superior longitudinal muscle and transverse muscle of the tongue). Muscle thickness shows the presence of atrophy or, in case of dystrophinopathies, hypertrophy of affected muscles. Hypertrophy is an increase in the size of muscle fibers without an increase in connective tissue, while pseudohypertrophy is an increase in the size of the muscle as a consequence of infiltration by fat and fibrosis.[15](#mus26771-bib-0015){ref-type="ref"} The mean echogenicity of selected regions of interest was calculated using the histogram function in a custom software program for quantitative muscle image analysis (QUMIA) developed at our center, resulting in a number between 0 and 255.[16](#mus26771-bib-0016){ref-type="ref"} We previously reported our reference values for healthy subjects.[9](#mus26771-bib-0009){ref-type="ref"}, [10](#mus26771-bib-0010){ref-type="ref"}, [11](#mus26771-bib-0011){ref-type="ref"} With these data, the muscle thickness and echogenicity of the orofacial muscles were described as z‐scores. z‐Scores above 2 were considered to be abnormal.[10](#mus26771-bib-0010){ref-type="ref"}, [17](#mus26771-bib-0017){ref-type="ref"}

2.3. Statistical analysis {#mus26771-sec-0012}
-------------------------

All statistical analyses were performed using IBM SPSS, version 22.0 (IBM Corp, Chicago, IL). Descriptive statistics were used to report the patient characteristics and the z‐scores of the 6MWT, MBF, and QMUS results. For comparing the two groups (DMD and BMD) with respect to age, weight, height, and z‐scores of the 6MWT, MBF and QMUS results, two‐sided independent‐samples Mann--Whitney *U* tests with a significance level of .05 were used. A nonparametric test was chosen because of the small sample size.

3. RESULTS {#mus26771-sec-0013}
==========

3.1. Subjects {#mus26771-sec-0014}
-------------

The charts of 81 patients with DMD and 11 patients with BMD were reviewed for this study. Eleven of the 81 boys with DMD (14%) and all boys with BMD were in the early ambulatory stage and were included for further analysis. Table [1](#mus26771-tbl-0001){ref-type="table"} shows the age, height, and weight of the patients, the proportion with mastication and swallowing difficulties, and the percentage receiving treatment with corticosteroids. Age was significantly higher for the BMD patients, as were height and weight.

###### 

Characteristics of the included patients in the early ambulatory stage (n = 22)

                              DMD (*N* = 11) Mean ± SD/N (%)   BMD (*N = 11)* Mean ± SD/N (%)   *P‐*value
  --------------------------- -------------------------------- -------------------------------- -----------
  Age (years)                 7.7 ± 1.7                        10.7 ± 2.4                       .004
  Height (cm)                 122.5 ± 12.2                     144.3 ± 15.2                     .002
  Weight (kg)                 24.8 ± 5.8                       38.3 ± 10.2                      .002
  Mastication difficulties    3 (27%)                          2 (18%)                          
  Swallowing difficulties     1 (9%)                           1 (9%)                           
  Corticosteroids treatment   9 (82%)                          1 (9%)                           

3.2. 6MWT {#mus26771-sec-0015}
---------

The mean distance on the 6MWT in the boys with BMD was 512.0 m (range, 420--615 m). DMD patients walked a mean of 359.6 m (range, 288--435 m). Boys with DMD had a significantly lower z‐score on the 6MWT than boys with BMD, indicating a lower walking capacity in the former (Table [2](#mus26771-tbl-0002){ref-type="table"}). An abnormal z‐score (\< −2) was observed in nine DMD and three BMD patients.

###### 

Assessments of the included patients in the early ambulatory stage (n = 22)

                            DMD (n = 11)   BMD (n = 11)   
  ------------------------- -------------- -------------- ----------------------------------------------
  6MWT                      −3.2 ± 0.9     −1.5 ± 1.1     .006[\*](#mus26771-note-0003){ref-type="fn"}
  Masseter muscle                                         
  MT                        −0.0 ± 0.6     −0.1 ± 0.6     .806
  EG                        3.5 ± 1.4      3.1 ± 1.3      .468
  Temporalis muscle                                       
  MT                        0.0 ± 1.0      1.0 ± 1.1      .040[\*](#mus26771-note-0003){ref-type="fn"}
  EG                        2.4 ± 1.8      2.3 ± 1.4      .878
  Digastric muscle                                        
  MT                        0.5 ± 1.2      −0.1 ± 1.2     .242
  EG                        2.4 ± 2.2      2.1 ± 1.6      .468
  Geniohyoid muscle                                       
  EG                        0.8 ± 1.6      1.3 ± 1.3      .352
  Transverse muscle                                       
  EG                        2.2 ± 1.4      1.6 ± 1.2      .300
  Superior long. Muscle                                   
  EG                        0.9 ± 0.8      0.9 ± 0.9      .971
  Thickness of the tongue   −0.2 ± 0.8     −0.3 ± 1.0     .770
  MBF                       −0.5 ± 0.6     −1.1 ± 0.9     .065

MT, muscle thickness; EG, echogenicity.

6MWT, MT, EG, thickness of the tongue and MBF were described in z‐scores.

Statistically significant differences in z‐scores between DMD and BMD patients, determined with independent samples Mann--Whitney *U* tests.

3.3. Thickness and echogenicity of orofacial muscles {#mus26771-sec-0016}
----------------------------------------------------

Table [2](#mus26771-tbl-0002){ref-type="table"} shows the means and standard deviations of the z‐scores for muscle thickness and echogenicity of the orofacial muscles. There were no significant differences in these measures between patients with BMD and DMD, except for the thickness of the temporalis muscle, which was significantly greater in patients with BMD. The thickness of the temporalis muscle was abnormal (z‐score \> 2) in two of the BMD patients and none of the DMD patients. The echogenicity of the temporalis muscle was also abnormal in these two BMD patients. The echogenicity of the masseter muscle was abnormal in eight of the BMD and 10 of the DMD patients. The thickness of the masseter muscle was normal in all patients. Hypertrophy of the tongue did not occur in either DMD or BMD patients.

3.4. MBF {#mus26771-sec-0017}
--------

The mean MBF of DMD patients was 74.8 N with a standard deviation of 23.5 N. BMD patients scored a mean MBF of 87.6 N with a standard deviation of 49.9 N. When corrected for height, MBF was lower in patients with BMD than in patients with DMD. This difference, however, did not reach significance (Table [2](#mus26771-tbl-0002){ref-type="table"}).

4. DISCUSSION {#mus26771-sec-0018}
=============

Our results show that, despite the better ambulatory capacity of BMD patients, the orofacial muscles are at least as severely affected in BMD as in DMD patients, which confirms our hypothesis. Indeed, the proportion of patients in our cohort with mastication and swallowing difficulties in the early ambulatory stage was equal for DMD and BMD patients. The prevalence of these difficulties in the DMD group was comparable to a previous study reporting a different cohort of DMD patients.[2](#mus26771-bib-0002){ref-type="ref"} In the same study, MBF was measured in DMD patients in the early ambulatory stage and these results were similar to the MBF results in the present study.[2](#mus26771-bib-0002){ref-type="ref"} Despite their better ambulatory capacity, BMD patients did not differ from DMD patients with regard to MBF.

In addition, in the present study, the temporalis muscle was significantly thicker in patients with BMD with an abnormal z‐score for echogenicity, showing a relatively early manifestation of pseudohypertrophy of this muscle in BMD patients. Pseudohypertrophy of the temporalis muscle has previously been observed on MRI in DMD patients who were 8--16 years old.[18](#mus26771-bib-0018){ref-type="ref"} In our cohort, pseudohypertrophy of the temporalis muscle (z‐score muscle thickness \> 2) was present in two BMD patients of 5--14 years old, but in none of the DMD patients. Straathof et al. stated that it remains unclear whether the increased muscle mass of the temporalis muscle results in an increased or a decreased bite force,[18](#mus26771-bib-0018){ref-type="ref"} but it seems likely that the limited MBF in early stages of DMD and BMD is probably due to the early dystrophic changes of the masseter muscle and the pseudohypertrophy of the temporalis muscle.

An interesting question is why BMD patients would have early involvement of masticatory muscles. One explanation may be that only one patient in the BMD group used corticosteroids. Corticosteroid treatment in DMD patients usually starts as soon as motor development reaches a plateau phase.[12](#mus26771-bib-0012){ref-type="ref"} In BMD patients, however, there is no guideline for starting corticosteroid treatment. It is unknown whether corticosteroid treatment may have a protective effect on the orofacial muscles. Previous studies showed early cardiomyopathy in BMD patients. In a study of Bredman et al. a cardiac‐specific myosin was found in the masticatory muscles, but not in other skeletal muscles,[19](#mus26771-bib-0019){ref-type="ref"} which points at another possible explanation for early involvement of the masticatory muscles in BMD. Further investigation is warranted to gain insight into why early dystrophic changes would occur in the cardiac and masticatory muscles in BMD patients.

Our results showed no differences in dystrophic changes between DMD and BMD patients in the early ambulatory stage regarding the muscles that are responsible for laryngeal elevation (digastric and geniohyoid muscles). These findings confirm the results of previous research, showing that dystrophic changes of the submental muscles occur in a relatively late stage of DMD.[20](#mus26771-bib-0020){ref-type="ref"} Changes in the submental muscles at a later stage may still lead to differences in laryngeal elevation between older DMD and BMD patients.[8](#mus26771-bib-0008){ref-type="ref"} Our results complement the findings of Yamada et al. 2017[5](#mus26771-bib-0005){ref-type="ref"} who used videofluoroscopy and found that swallowing difficulties in BMD patients are similar to the difficulties in DMD patients, when patients are matched according to functional ability. We found that BMD patients show dystrophic changes of masticatory muscles earlier than DMD patients, relatively to their gait capacity.

A limitation of the current study is the small number of patients. This could have led to an equal number of patients with swallowing and mastication difficulties in both groups. A strength is that the findings were confirmed using different assessment tools (questionnaire, QMUS, and MBF). Analyses of larger groups of patients and a longitudinal follow up through the different ambulatory stages are needed to determine more specific differences in dystrophic changes of both limb and orofacial muscles between DMD and BMD patients. We believe that the results of our study warrant awareness of dysphagia and mastication and swallowing difficulties in BMD patients, even when ambulation is still well preserved. When there is a clinical suspicion of dysphagia, instrumental assessment is recommended.
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